A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study.

PubWeight™: 1.21‹?› | Rank: Top 10%

🔗 View Article (PMC 2963483)

Published in Diabetes Care on August 03, 2010

Authors

L Maria Belalcazar1, David M Reboussin, Steven M Haffner, Ron C Hoogeveen, Andrea M Kriska, Dawn C Schwenke, Russell P Tracy, F Xavier Pi-Sunyer, Christie M Ballantyne, Look AHEAD Research Group

Author Affiliations

1: Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA.

Associated clinical trials:

Look AHEAD: Action for Health in Diabetes (LookAHEAD) | NCT00017953

Articles citing this

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68

Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res (2012) 1.50

Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet (2015) 1.38

Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring) (2013) 1.04

Weight change in control group participants in behavioural weight loss interventions: a systematic review and meta-regression study. BMC Med Res Methodol (2012) 1.01

Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol (2011) 0.93

Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol (2014) 0.89

Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism (2013) 0.87

Knowledge, Attitudes, and Current Practices of Canadian Physiotherapists in Preventing and Managing Diabetes. Physiother Can (2016) 0.87

Systemic inflammation is associated with ovarian follicular dynamics during the human menstrual cycle. PLoS One (2013) 0.85

Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. J Pharmacol Pharmacother (2011) 0.85

Effects of lifestyle education program for type 2 diabetes patients in clinics: a cluster randomized controlled trial. BMC Public Health (2013) 0.84

Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. Med Sci Sports Exerc (2014) 0.81

Effect of dietary composition of weight loss diets on high-sensitivity c-reactive protein: the Randomized POUNDS LOST trial. Obesity (Silver Spring) (2013) 0.80

Fatness but Not Fitness Relative to the Fat-Free Mass Is Related to C-Reactive Protein in 18 Year-Old Adolescents. PLoS One (2015) 0.79

Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care (2016) 0.77

Influence of lifestyle factors on inflammation in men and women with type 2 diabetes: results from the National Health and Nutrition Examination Survey, 1999-2004. Ann Behav Med (2012) 0.77

Impact of weight loss on ankle-brachial index and interartery blood pressures. Obesity (Silver Spring) (2014) 0.76

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Curr Atheroscler Rep (2014) 0.76

Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. PLoS One (2015) 0.76

Dietary intervention induces flow of changes within biomarkers of lipids, inflammation, liver enzymes, and glycemic control. Nutrition (2011) 0.76

Time variability of C-reactive protein: implications for clinical risk stratification. PLoS One (2013) 0.75

The role of bile acid sequestrants in the management of type 2 diabetes mellitus. Metab Syndr Relat Disord (2010) 0.75

Readability and content analysis of lifestyle education resources for weight management in Australian general practice. BMC Obes (2016) 0.75

Effect of Bariatric Weight Loss on the Adipose Lipolytic Transcriptome in Obese Humans. Mediators Inflamm (2015) 0.75

The Predictive Role of Tooth Extractions, Oral Infections, and hs-C-Reactive Protein for Mortality in Individuals with and without Diabetes: A Prospective Cohort Study of a 12 1/2-Year Follow-Up. J Diabetes Res (2017) 0.75

Articles cited by this

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 16.23

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2008) 15.35

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest (2006) 12.32

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97

Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation (2002) 6.26

T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23

Antiinflammatory properties of HDL. Circ Res (2004) 5.41

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 4.76

Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res (2006) 4.30

Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab (2006) 3.04

Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care (1999) 3.01

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46

Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond) (2009) 2.32

Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ (2005) 1.90

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75

The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol (2006) 1.42

Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol (2008) 1.36

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA (2009) 1.27

Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation (2002) 1.19

The inverse association between cardiorespiratory fitness and C-reactive protein is mediated by autonomic function: a possible role of the cholinergic antiinflammatory pathway. Mol Med (2009) 0.97

Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia (2006) 0.90

Characterization of high density lipoprotein binding to human adipocyte plasma membranes. J Clin Invest (1985) 0.88

Articles by these authors

Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol (2002) 35.63

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 23.97

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation (2005) 8.59

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93

Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09

Decline in physical activity in black girls and white girls during adolescence. N Engl J Med (2002) 7.06

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med (2006) 6.58

The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53

T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12

Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00

Lifetime risks of cardiovascular disease. N Engl J Med (2012) 5.95

HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90

Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med (2008) 5.86

Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79

Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care (2011) 5.50

Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA (2005) 5.50

Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43

Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol (2006) 5.28

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol (2013) 5.24

Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15

NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02

Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med (2002) 4.97

Inflammation as a risk factor for atrial fibrillation. Circulation (2003) 4.95

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA (2013) 4.85

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67

Relation between the changes in physical activity and body-mass index during adolescence: a multicentre longitudinal study. Lancet (2005) 4.65

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA (2004) 4.54

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30

The 6-min walk test: a quick measure of functional status in elderly adults. Chest (2003) 4.29

Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28

An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14

One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) (2009) 4.08

Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care (2005) 3.96

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2004) 3.96

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol (2012) 3.91

Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76

Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 3.68

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68

Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) (2011) 3.62

Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61

Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care (2004) 3.51

Thyroid status, cardiovascular risk, and mortality in older adults. JAMA (2006) 3.50

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45

Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med (2006) 3.38

Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA (2003) 3.36

Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med (2013) 3.30

A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med (2009) 3.27

Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA (2006) 3.26

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol (2006) 3.11

Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) (2014) 3.10

Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09

Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07

Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med (2002) 3.04

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med (2005) 3.00

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00

Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA (2013) 2.98

Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care (2004) 2.92

Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92

Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91

Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med (2012) 2.90

Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med (2009) 2.88

Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation (2003) 2.88